These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971 [TBL] [Abstract][Full Text] [Related]
24. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Zhang W; Li X; Ye T; Chen F; Sun X; Kong J; Yang X; Pan W; Li S Int J Pharm; 2013 Sep; 454(1):354-66. PubMed ID: 23876384 [TBL] [Abstract][Full Text] [Related]
25. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Shete H; Chatterjee S; De A; Patravale V Int J Pharm; 2013 Sep; 454(1):584-92. PubMed ID: 23535344 [TBL] [Abstract][Full Text] [Related]
26. Replacing heme with paclitaxel to prepare drug-loaded globin nanoassembles for CD163 targeting. Meng Z; Yang X; Hu D; Wang K; Zhi F; Chen X; Gong G; Wu J; Hu Y J Pharm Sci; 2015 Mar; 104(3):1045-55. PubMed ID: 25640195 [TBL] [Abstract][Full Text] [Related]
27. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel. Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Guo X; Chen D Int J Pharm; 2015 Mar; 480(1-2):116-27. PubMed ID: 25615984 [TBL] [Abstract][Full Text] [Related]
28. Surface density of polyarginine influence the size, zeta potential, cellular uptake and tissue distribution of the nanostructured lipid carrier. Sun M; Zhu Z; Wang H; Han C; Liu D; Tian L; Yang X; Pan W Drug Deliv; 2017 Nov; 24(1):519-526. PubMed ID: 28181841 [TBL] [Abstract][Full Text] [Related]
29. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Gao W; Xiang B; Meng TT; Liu F; Qi XR Biomaterials; 2013 May; 34(16):4137-4149. PubMed ID: 23453200 [TBL] [Abstract][Full Text] [Related]
30. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema. Gao S; Tian B; Han J; Zhang J; Shi Y; Lv Q; Li K Int J Nanomedicine; 2019; 14():6135-6150. PubMed ID: 31447556 [No Abstract] [Full Text] [Related]
31. Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization. Vaidya B; Vyas SP J Drug Target; 2012 May; 20(4):372-80. PubMed ID: 22339366 [TBL] [Abstract][Full Text] [Related]
32. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment. Yu D; Li W; Zhang Y; Zhang B Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131 [TBL] [Abstract][Full Text] [Related]
33. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction. Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053 [TBL] [Abstract][Full Text] [Related]
34. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma. Pandey V; Gajbhiye KR; Soni V Drug Deliv; 2015 Feb; 22(2):199-205. PubMed ID: 24467582 [TBL] [Abstract][Full Text] [Related]
35. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous? Li C; Li Y; Gao Y; Wei N; Zhao X; Wang C; Li Y; Xiu X; Cui J Int J Pharm; 2014 Jul; 468(1-2):15-25. PubMed ID: 24709221 [TBL] [Abstract][Full Text] [Related]
37. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer. Liu Y; Ng Y; Toh MR; Chiu GNC J Control Release; 2015 Dec; 220(Pt A):438-446. PubMed ID: 26551345 [TBL] [Abstract][Full Text] [Related]
38. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519 [TBL] [Abstract][Full Text] [Related]
39. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332 [TBL] [Abstract][Full Text] [Related]
40. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. How CW; Rasedee A; Manickam S; Rosli R Colloids Surf B Biointerfaces; 2013 Dec; 112():393-9. PubMed ID: 24036474 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]